Mohamed Tolba, MD
Interventional Pain Medicine · Conway, ARNPI 1356635486
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Boston Scientific at 56.8% of the total. 2025 is the largest year on record at $483, 2.9 times the $166 reported in 2019. That places this record below the midpoint for interventional pain medicine clinicians in AR, where the typical reported total is $3,706.
Across 34 payments — averaging $32.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$625
- Nevro Corp.$92
- Pacira Therapeutics, Inc.$65
- Pfizer$46
- Collegium Pharmaceutical, Inc.$39
- Zyla Life Sciences, Inc.$38
- plus $195 from 10 others
What the payments were for
- Food & beverage$1,101100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $625 |
| Nevro Corp. | 2 | $92 |
| Pacira Therapeutics, Inc. | 3 | $65 |
| Pfizer | 2 | $46 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Zyla Life Sciences, Inc. | 3 | $38 |
| Baudax Bio Inc. | 2 | $37 |
| Nalu Medical, Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $24 |
| Si-bone, Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Vertex | 1 | $17 |
| GRT US Holding, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Saluda Medical Americas, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,101 in reported general payments places this provider in the 25th percentile of 29 interventional pain medicine providers in Arkansas.
See all interventional pain medicine providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,568 | $46,282 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,068 | $25,113 |
| Oxycodone Hcl | 897 | $13,070 |
| LyricaPregabalin | 11 | $9,695 |
| Gabapentin | 625 | $8,979 |
| MovantikNaloxegol Oxalate | 19 | $8,522 |
| Pregabalin | 353 | $8,448 |
| Xtampza ErOxycodone Myristate | 14 | $8,201 |
| Fentanyl | 67 | $4,363 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $4,295 |
| OxycontinOxycodone Hcl | 12 | $4,067 |
| Tizanidine Hcl | 457 | $3,880 |
| Morphine Sulfate ErMorphine Sulfate | 147 | $3,591 |
| Cyclobenzaprine Hcl | 359 | $3,235 |
| Morphine Sulfate | 119 | $2,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerLyrica | $46 | $9,69511 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $39 | $8,20114 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl | $16 | $7,255155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 29 interventional pain medicine providers in Arkansas.
Other interventional pain medicine in Conway
- Sameer JainBryant$56K
- Ryan KrafftMountain Home$51K
- Robert CannonFayetteville$15K
- Amir QureshiLittle Rock$14K
- Brett WhatcottFort Smith$10K
- Mohammad EldeebFort Smith$9K
- Ahmed GhalebLittle Rock$7K
- Michael AdamsMena$6K
- Majid SaleemLittle Rock$5K
- Gary FrankowskiLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.